BGB-A3055 + tislelizumab + chemotherapy

BGB-A3055 + tislelizumab + chemotherapy is an investigational combination therapy involving three components: - **BGB-A3055**: a fully humanized, afucosylated monoclonal antibody targeting C-C motif chemokine receptor 8 (CCR8), designed to deplete regulatory T cells selectively within the tumor microenvironment by blocking CCL1-CCR8 signaling and inducing antibody-dependent cellular cytotoxicity (ADCC)[2][4]. - **Tislelizumab**: a humanized IgG4 anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, enhancing the immune system's anti-tumor response. Tislelizumab (BGB-A317) is approved for some cancers in China and is under investigation worldwide[5]. - **Chemotherapy**: refers broadly to cytotoxic agents used to target rapidly dividing cancer cells, commonly included in combination regimens for synergistic anti-tumor efficacy. This combination is being evaluated in early-phase clinical trials for patients with advanced or metastatic solid tumors, particularly those with high CCR8 expression, to assess safety, tolerability, and preliminary efficacy[1][3][4][5].